PYC 8.11% 17.0¢ pyc therapeutics limited

finance news network interview with paul watt , page-2

  1. 597 Posts.
    Doesn't it make you wonder why if the story is so good nobody gives a damn? Maybe its just sales talk. All puff.

    Roche deal was peanuts. So will the others be. Even though they are talking about being cash fow positive soon, up front licencing cash does not get PE rated because its not product in market.

 
watchlist Created with Sketch. Add PYC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.